Wat is de prijs voor Intercept Pharmaceuticals, Inc. (ICPT)

Het prijs van Intercept Pharmaceuticals, Inc. (ICPT) is $19.00

Wat is de marktkapitalisatie voor Intercept Pharmaceuticals, Inc. (ICPT)

Marktkapitalisatie voorIntercept Pharmaceuticals, Inc. (ICPT) is $629.64M

Intercept Pharmaceuticals, Inc. (ICPT) K/B-verhouding

Intercept Pharmaceuticals, Inc. is a biopharmaceutical firm specializing in the advancement and market launch of therapies designed to treat progressive, non-viral liver conditions. Its operational reach spans the United States, Europe, and Canada. The company currently markets Ocaliva, a medication functioning as a farnesoid X receptor (FXR) agonist. This drug is approved for the treatment of primary biliary cholangitis (PBC) in adults, specifically when administered alongside ursodeoxycholic acid. Beyond its existing approved indications, Intercept is actively investigating Ocaliva's potential for additional uses, notably including nonalcoholic steatohepatitis (NASH). Concurrently, it is progressing other drug candidates through various clinical and preclinical stages of development. In a collaborative effort, the company holds a licensing agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. Intercept distributes its products through a dual approach, utilizing both its proprietary commercial organization and a network of external third-party distributors. The company was founded in 2002 and is headquartered in New York, New York.

Jaar	P/B-ratio	Wijzigen
Niet genoeg gegevens voor de verstrekte datums.

Jaar

P/B-ratio

Wijzigen

Niet genoeg gegevens voor de verstrekte datums.

Bedrijf	P/B-ratio	Verschil in P/B-ratio	Land
Vertex Pharmaceuticals Incorporated VRTX.US	6.3419	-	US
Argenx SE ARGX.US	6.2413	-	NL
CSL Limited CSL.AX	2.5054	-	AU
Moderna, Inc. MRNA.US	3.7087	-	US
Lonza Group AG LONN.SW	-	-	CH

Bedrijf

P/B-ratio

Verschil in P/B-ratio

Land